NCT05704933 2026-04-06
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Completed
Clinical Trials
9 trialsNCT02652455 2025-08-19
Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Completed
NCT04581382 2025-07-10
Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT03162731 2025-04-29
Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage III-IVB Head and Neck Cancer
Thomas Jefferson University
Phase EARLY_PHASE1 Completed
NCT03311958 2025-04-06
Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance
Fox Chase Cancer Center
Phase EARLY_PHASE1 Completed
NCT03970252 2024-08-09
Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed
NCT03316274 2024-06-25
Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma
University of California, San Francisco
Phase EARLY_PHASE1 Completed
NCT03575598 2023-07-27
SNOW
University Health Network, Toronto
Phase EARLY_PHASE1 Completed
NCT03224871 2020-04-07
UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.
University of California, Davis
Phase EARLY_PHASE1 Completed